CLAIMS

1. A composition comprising mesenchymal lineage precursor or stem cells (MLPSCs) in which the MLPSCs are previously cryopreserved such that, after thawing, the cells inhibit proliferation of activated T cells expressing IL-2Rα in a sample of PBMC comprising such activated T cells by at least about 65%, wherein the inhibition of proliferation of activated T cells is measured by co-incubation of the MLPSCs and PBMCs at a ratio of 1 MLPSC:5 PBMC, or less, and determining the level of inhibition of IL-2Rα expression in the activated T cells.

2. A composition according to Claim 1, in which co-incubation of mesenchymal lineage precursor or stem cells with PBMC at a ratio of 1 mesenchymal lineage precursor or stem cell:10 PBMC, or less, inhibits T cell proliferation by at least about 65%.

3. A composition according to Claim 1 , in which co-incubation of mesenchymal lineage precursor or stem cells with PBMC at a ratio of 1 mesenchymal lineage precursor stem cell:50 PBMC, or less, inhibits T cell proliferation by at least about 65%.

4. A composition according to Claim 1, in which co-incubation of mesenchymal lineage stem cells with PBMC at a ratio of 1 mesenchymal lineage precursor or stem cell:100 PBMC, or less, inhibits T cell proliferation by at least about 65%.

5. A composition according to any preceding claim, in which co-incubation of mesenchymal lineage precursor or stem cells with PBMC at a ratio of 1 mesenchymal lineage precursor or stem cell:5 PBMC, or less, inhibits T cell proliferation by at least about 70%.

6. A composition according to any preceding claim, in which co-incubation of mesenchymal lineage precursor or stem cells with PBMC at a ratio of 1 mesenchymal lineage precursor or stem cell:5 PBMC, or less, inhibits T cell proliferation by at least about 80%.

7. A composition according to any preceding claim, in which the mesenchymal lineage precursor or stem cells express TNFR1 in an amount of at least 270 pg/ml.

8. A composition according to any of Claims 1 to 6, in which the mesenchymal lineage precursor or stem cells express TNFR1 in an amount of at least 300 pg/ml.

9. A composition according to any of Claims 1 to 6, in which the mesenchymal lineage precursor or stem cells express TNFR1 in an amount of at least 320 pg/ml.

10. A composition according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are isolated by immunoselection.

11. A composition according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are culture expanded mesenchymal stem cells.

12. Use of a composition comprising mesenchymal lineage precursor or stem cells according to any preceding claim in the manufacture of a medicament for treating a T-cell mediated inflammatory disorder in a subject in need thereof.

13. Use of a composition comprising mesenchymal lineage precursor or stem cells according to any of Claims 1 to 11 in the manufacture of a medicament for alleviating the development of, or treating graft versus host disease (GVHD) in a subject.

14. Use according to Claim 12 or 13, in which the composition comprises a dose of less than 3×10^6 cells/kg.

15. Use according to Claim 12 or 13, in which the composition comprises a dose of about 2×10^6 cells/kg.

16. Use according to Claim 12 or 13 in which the composition comprises 2×10^6 cells/kg.